Active Ingredient History

  • Now
Cyclothiazide was presumably developed by Eli Lilly for the treatment of hypertension. It is believed that the drug, which belongs to the class of thiazide diuretics, exerts its action by inhibitin sodium reabsorption in the renal tubules. In 1993 it was discovered that cyclothiazide stimulates AMPA receptors thus inducing seizure behavior.   NCATS

  • SMILES: NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C3CC4CC3C=C4
  • Mol. Mass: 389.878
  • ALogP: 1.23
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No
35483 | 6-chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide | 6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide | 6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide | 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide | anhydron | ciclotiazida | ciclotiazide | cyclothiazide | cyclothiazidum | fluidil


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue